Cargando…
HbA(1c) for Diabetes Screening in Acute Coronary Syndrome: time for a reappraisal of the guidelines?
OBJECTIVE: Diabetes is highly prevalent in individuals with acute coronary syndrome (ACS). Current NICE guidelines recommend diabetes screening of hyperglycaemic patients using a fasting plasma glucose after 4 days from admission. In 2012 the World Health Organisation (WHO) approved the use of HbA(1...
Autores principales: | McCune, C, Maynard, S, McClements, B, Lindsay, JR |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Ulster Medical Society
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4642257/ https://www.ncbi.nlm.nih.gov/pubmed/26668415 |
Ejemplares similares
-
Performance of HbA(1c) and Fasting Plasma Glucose in Screening for Diabetes in Patients Undergoing Coronary Angiography
por: Wang, Jun-Sing, et al.
Publicado: (2013) -
Measurement of HbA(1c) and HbA(2) by Capillarys 2 Flex Piercing HbA(1c) programme for simultaneous management of diabetes and screening for thalassemia
por: Ke, Peifeng, et al.
Publicado: (2017) -
HbA(1c) and Coronary Heart Disease Risk Among Diabetic Patients
por: Zhao, Wenhui, et al.
Publicado: (2014) -
HbA1c Screening for Diabetes in Patients with Acute Coronary Syndrome: A Worthwhile Test or a Pitfall?
por: Józwa, Robert, et al.
Publicado: (2021) -
The True Value of HbA1c as a Predictor of Diabetic Complications: Simulations of HbA1c Variables
por: Lind, Marcus, et al.
Publicado: (2009)